NASDAQ:ALIM - Alimera Sciences Stock Price, Forecast & News

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Alimera Sciences's stock reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

Alimera Sciences Inc (NASDAQ:ALIM) posted its quarterly earnings results on Tuesday, October, 29th. The biopharmaceutical company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60). The biopharmaceutical company earned $12.85 million during the quarter, compared to analyst estimates of $12.75 million. View Alimera Sciences' Earnings History.

Alimera Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Alimera Sciences.

3 Wall Street analysts have issued 1 year price targets for Alimera Sciences' shares. Their forecasts range from $15.00 to $45.00. On average, they expect Alimera Sciences' share price to reach $30.00 in the next year. This suggests a possible upside of 366.6% from the stock's current price. View Analyst Price Targets for Alimera Sciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alimera Sciences.

News stories about ALIM stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Alimera Sciences earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Alimera Sciences.

Alimera Sciences saw a drop in short interest in January. As of January 31st, there was short interest totalling 31,900 shares, a drop of 57.0% from the January 15th total of 74,100 shares. Based on an average trading volume of 76,200 shares, the short-interest ratio is presently 0.4 days. Approximately 0.8% of the shares of the company are sold short. View Alimera Sciences' Current Options Chain.

Some companies that are related to Alimera Sciences include ProMetic Life Sciences (PFSCF), AcelRx Pharmaceuticals (ACRX), Corvus Pharmaceuticals (CRVS), Cassava Sciences (SAVA), Eton Pharmaceuticals (ETON), TapImmune (MRKR), Helix Biopharma (HBPCF), Marinus Pharmaceuticals (MRNS), Menlo Therapeutics (MNLO), Galmed Pharmaceuticals (GLMD), Genprex (GNPX), CannTrust (CTST), NeuBase Therapeutics (NBSE), Paratek Pharmaceuticals (PRTK) and Otonomy (OTIC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include Eyepoint Pharmaceuticals (EYPT), NovaBay Pharmaceuticals (NBY), Opko Health (OPK), Agenus (AGEN), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), CorMedix (CRMD), Aldeyra Therapeutics (ALDX) and Advanced Micro Devices (AMD).

Alimera Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.52%), Royce & Associates LP (0.93%) and JW Asset Management LLC (0.55%). Company insiders that own Alimera Sciences stock include James R Largent, John Philip Jones, John Snisarenko and Richard S Eiswirth Jr. View Institutional Ownership Trends for Alimera Sciences.

ALIM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Royce & Associates LP and JW Asset Management LLC. View Insider Buying and Selling for Alimera Sciences.

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALIM stock can currently be purchased for approximately $6.43.

Alimera Sciences has a market capitalization of $31.96 million and generates $46.97 million in revenue each year. Alimera Sciences employs 124 workers across the globe.View Additional Information About Alimera Sciences.

The official website for Alimera Sciences is http://www.alimerasciences.com/.

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]